Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing

被引：88

作者：

Belley, Adam ^{[1
]}

McKay, Geoffrey A. ^{[1
]}

Arhin, Francis F. ^{[1
]}

Sarmiento, Ingrid ^{[1
]}

Beaulieu, Sylvain ^{[1
]}

Fadhil, Ibthihal ^{[1
]}

Parr, Thomas R., Jr. ^{[1
]}

Moeck, Gregory ^{[1
]}

机构：

[1] Med Co, St Laurent, PQ H4S 2A1, Canada

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2010年 / 54卷 / 12期

关键词：

LIPOGLYCOPEPTIDE; TELAVANCIN; DAPTOMYCIN;

D O I：

10.1128/AAC.00760-10

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Oritavancin is an investigational lipoglycopeptide in clinical development for the treatment of acute bacterial skin and skin structure infections. In this study, we demonstrate that oritavancin causes bacterial membrane depolarization and permeabilization leading to cell death of Gram-positive pathogens and that these effects are attributable to the 4'-chlorobiphenylmethyl group of the molecule.

引用

收藏

页码：5369 / 5371

页数：3

相关论文

共 19 条

[1]

[Anonymous], 2018, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically

[2]

approved standard-10th ed

[3] Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA) [J].

Appelbaum, Peter C. .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 30 (05) :398-408

[4] Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates [J].

Arhin, Francis F. ;

Draghi, Deborah C. ;

Pillar, Chris M. ;

Parr, Thomas R., Jr. ;

Moeck, Gregory ;

Sahm, Daniel F. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (11) :4762-4771

[5] Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin [J].

Arhin, Francis F. ;

Sarmiento, Ingrid ;

Parr, Thomas R., Jr. ;

Moeck, Gregory .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (04) :868-870

[6] Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro [J].

Belley, Adam ;

Neesham-Grenon, Eve ;

McKay, Geoffrey ;

Arhin, Francis F. ;

Harris, Robert ;

Beveridge, Terry ;

Parr, Thomas R., Jr. ;

Moeck, Gregory .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) :918-925

[7] Vancomycin resistance in gram-positive cocci [J].

Courvalin, P .

CLINICAL INFECTIOUS DISEASES, 2006, 42 :S25-S34

[8] Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization [J].

Domenech, Oscar ;

Francius, Gregory ;

Tulkens, Paul M. ;

Van Bambeke, Francoise ;

Dufrene, Yves ;

Mingeot-Leclercq, Marie-Paule .

BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2009, 1788 (09) :1832-1840

[9] Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus [J].

Higgins, DL ;

Chang, R ;

Debabov, DV ;

Leung, J ;

Wu, T ;

Krause, KA ;

Sandvik, E ;

Hubbard, JM ;

Kaniga, K ;

Schmidt, DE ;

Gao, QF ;

Cass, RT ;

Karr, DE ;

Benton, BM ;

Humphrey, PP .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :1127-1134

[10] Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis, in Staphylococcus aureus [J].

Kim, Sung Joon ;

Cegelski, Lynette ;

Stueber, Dirk ;

Singh, Manmilan ;

Dietrich, Evelyne ;

Tanaka, Kelly S. E. ;

Parr, Thomas R., Jr. ;

Far, Adel Rafal ;

Schaefer, Jacob .

JOURNAL OF MOLECULAR BIOLOGY, 2008, 377 (01) :281-293